BCIQ Profiles

Company Profile Report
0304 QT Deals
BioCentury & Getty Images


March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

Mar 5, 2021 | 1:33 AM GMT

A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round

Read the full 632 word article

How to gain access

Continue reading with a
two-week free trial.